Efficacy of UVA1 phototherapy in 230 patients with various skin diseases

Rombold, Stephanie; Lobisch, K.; Katzer, K.; Grazziotin, Thaís Corsetti; Ring, Johannes; Eberlein, Bernadette

doi:10.1111/j.1600-0781.2008.00328.x

Cited by 92 publications

(68 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was suggested that similar to therapy outcomes in LoS, low- dose UV-A1 therapy seems to be a beneficial and well-tolerated therapy modality for extragenital LiS (32). Rombold et al (11) also observed beneficial outcome for LiS patients managed with medium-dose UV-A1 (cumulative dose: 1,018 ± 575.3 J/cm 2 ).…”

Section: Introductionmentioning

confidence: 88%

Ultraviolet A1 Phototherapy for Fibrosing Conditions

Gambichler

Schmitz

2018

Front. Med.

View full text Add to dashboard Cite

In this article we describe efficacy and safety aspects of ultraviolet A1 (UV-A1) phototherapy in fibrosing conditions. UV-A1 is a specific phototherapeutic modality that is defined by a selective spectral range (340–400 nm). UV-A1 includes distinct modes of action qualifying this method for therapy of a variety of conditions, in particular fibrosing skin diseases. Concerning efficacy of UV-A1 phototherapy in fibrosing conditions, the best evidence obtained from randomized controlled trials exists for localized scleroderma. Moreover, fibrosing disorders such as lichen sclerosus and graft-vs.-host disease can be treated successfully by means of UV- A1. Regarding the optimal dosage regimen medium-dose UV-A1 seems to be linked to the best benefit/risk ratio. Possible acute adverse events of UV-A1 phototherapy include erythema and provocation of photodermatoses. Skin ageing and skin cancer formation belong to the chronic adverse events that may occur after long-term UV-A1 phototherapy.

show abstract

Section: Introductionmentioning

confidence: 88%

Ultraviolet A1 Phototherapy for Fibrosing Conditions

Gambichler

Schmitz

2018

Front. Med.

View full text Add to dashboard Cite

show abstract

“…The treatment regimens in-cluded daily phototherapy treatments 5 times per week which used fixed regimens similar to ours or were continued until clinical and/or histological clearance [14][15][16][17][18][19][20][21][22][23][24][25][26] . The rates of CR varied from 60 to 100% in studies of 4 to 19 patients [16,17,[19][20][21][22][23]26] and from no response to complete healing in case reports [14,15,18,24,25] . Forty years after the first use of PUVA in MF [27] , several heterogeneous studies with differences in patient selection, treatment protocols, and outcome variables have established the efficacy of PUVA and narrowband UVB in the treatment of MF [3] .…”

Section: Discussionmentioning

confidence: 99%

Ultraviolet A1 Phototherapy in the Treatment of Early Mycosis Fungoides

et al. 2017

View full text Add to dashboard Cite

Background: Phototherapy has been the mainstay of therapies for early mycosis fungoides (MF). The beneficial role of ultraviolet (UV) light on MF is suggested by the observation that lesions occur on non-sun-exposed areas. Therapeutic light sources that are available today are broadband UVB, psoralen and UVA, narrowband UVB, and long-wave UV (UVA1). Current literature provides increasing evidence on the use of UVA1 to treat MF. Aim: To investigate the treatment responses of early MF patients treated with fixed 30 J/cm² doses of UVA1 phototherapy. Material and Methods: Nineteen patients with early MF, stage IA-IIA of the TNM staging system, received fixed 30 J/cm² doses of UVA1, given 5 times weekly over 5 weeks. Therapeutic effectiveness was assessed by clinical examination and was confirmed by histological evaluation. Results: Of the 19 patients, complete responses were achieved in 12 (63%) and partial responses were achieved in 7 (37%) patients after UVA1 radiation exposures. During the study, UVA1 therapy was well tolerated. During the follow-up, 7 (58%) of the 12 patients with complete response relapsed within 3 months of the UVA1 therapy. Conclusion: The current study provides clinical and histological evidence for the effectiveness of UVA1 (30 J/cm² 5 times a week for 5 weeks) as a skin-directed therapy in the treatment of early MF; however, such a treatment failed to maintain a long and sustained response. Thus, studies to identify the optimal dosing protocol regarding the therapeutic efficacy, the factors affecting relapse time/rate, and the necessity of maintenance treatment are needed.

show abstract

“…Therapeutic effects of UVA1 therapy have been shown in patients with atopic eczema, lichen sclerosus et atrophicus, keratosis licehnoides chronica, prurigo nodularis, cutaneous T-cell lymphoma, granuloma annulare and scleroderma (8).…”

Section: Discussionmentioning

confidence: 99%

Uva1 Phototherapy in the Management of Sclerodermatous Graft-Versus-Host Disease (Gvhd): a report of two cases / Uva1 fototerapija u lečenju sklerodermatoznog oblika hronične Gvhd: Prikaz dva slučaja

Fassihi¹,

Iqbal²,

Garibaldinos³

et al. 2009

Serbian Journal of Dermatology and Venerology

View full text Add to dashboard Cite

Chronic graft-versus-host disease (GVHD) is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Approximately 10% of patients with GVHD develop sclerodermatous changes, which can cause significant morbidity and are often refractory to standard systemic immunosuppression. We present two cases of sclerodermatous GVHD. The first is a 39-year-old man, who had a matched sibling, undergoing allogeneic HSCT for severe aplastic anemia. The second patient is a 7-year-old boy, who had an allogeneic HSCT from his HLA-identical mother for acute myeloid leukemia (AML). Both patients presented with widespread sclerotic changes, resulting in joint contractures and significant functional difficulties. Studies have shown UVA1 phototherapy to be a promising and well tolerated treatment modality in patients with sclerotic skin diseases. Both of our patients were treated with UVA1, which resulted in a significant skin softening, improvement in joint mobility and quality of life. UVA1 appears to be an effective treatment for refractory sclerodermatous GVHD; however, long-term clinical studies in larger groups are needed to accurately evaluate its efficacy and safety.

show abstract

Efficacy of UVA1 phototherapy in 230 patients with various skin diseases

Abstract: Besides topical and systemic therapy, UVA1 radiation is a good option of treatment in various skin diseases. It is one of the first-line treatments for several sclerotic diseases and it often improves pruritus considerably.

Cited by 92 publications

References 35 publications

Ultraviolet A1 Phototherapy for Fibrosing Conditions

Ultraviolet A1 Phototherapy for Fibrosing Conditions

Ultraviolet A1 Phototherapy in the Treatment of Early Mycosis Fungoides

Uva1 Phototherapy in the Management of Sclerodermatous Graft-Versus-Host Disease (Gvhd): a report of two cases / Uva1 fototerapija u lečenju sklerodermatoznog oblika hronične Gvhd: Prikaz dva slučaja

Contact Info

Product

Resources

About